Reducing Overtreatment in Gynecologic Oncology: The Case for Less in Endometrial and Ovarian Cancer by Sarah M. Temkin et al.
May 2016 | Volume 6 | Article 1181
Mini Review
published: 09 May 2016
doi: 10.3389/fonc.2016.00118
Frontiers in Oncology | www.frontiersin.org
Edited by: 
Ben Davidson, 
Oslo University Hospital, Norway
Reviewed by: 
John Austin Vargo, 
University of Pittsburgh Cancer 
Institute, USA 
Connie Irene Diakos, 
University of Sydney, Australia
*Correspondence:
Sarah M. Temkin  
stemkin1@jhmi.edu
Specialty section: 
This article was submitted to 
Women's Cancer, 






Temkin SM, Tanner EJ, Dewdney SB 
and Minasian LM (2016) Reducing 
Overtreatment in Gynecologic 
Oncology: The Case for Less in 
Endometrial and Ovarian Cancer. 
Front. Oncol. 6:118. 
doi: 10.3389/fonc.2016.00118
Reducing Overtreatment in 
Gynecologic Oncology: The Case 
for Less in endometrial and Ovarian
Cancer
 
Sarah M. Temkin1*, Edward J. Tanner2, Summer B. Dewdney3 and Lori M. Minasian1
1 The Division of Cancer Prevention, The National Cancer Institute, National Institutes of Health, Bethesda, MD, USA, 2 The 
Kelly Gynecologic Oncology Service, Johns Hopkins School of Medicine, Baltimore, MD, USA, 3 Division of Gynecologic 
Oncology, Rush University School of Medicine, Chicago, IL, USA
A growing awareness of the harms of overtreatment in cancer care has reached physi-
cians, patients, health policy makers, and medical researchers. Overtreatment exposes 
patients to the risk of adverse events from procedures or medications that were not
necessary. This review examines common practices in gynecologic malignancies that 
are unlikely to produce direct benefit to patients with these malignancies, but are likely to 
produce harms. Specifically, we will explore the utility of lymphadenectomy and adjuvant 
radiation for women with early-stage endometrial cancer; and screening for recurrence 
and continuous chemotherapy for advanced-stage ovarian cancer patients.
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inTRODUCTiOn
The development of practical quality care measures has become a priority within the US health-care 
system. The Institute of Medicine (IOM) has identified three categories of health-care quality prob-
lems: underuse, overuse, and misuse (1–4). Underuse of effective therapies and misuse of services 
have received the most attention from quality improvement initiatives and patient safety efforts. 
However, recently, growing attention to an epidemic of overtreatment has been critically evaluated 
as problematic.
The term “overuse” in health care was introduced in 1991 in an editorial by Mark Chassin, as 
“the provision of health services when the risks outweigh their benefits” (5). The IOM first defined 
overuse in 1998 as the use of health-care resources and procedures in the absence of evidence that 
the service is beneficial (2). Overuse has been cited as a driver of the high cost of cancer in the United 
States (3, 4).
Overtreatment is a component of overuse defined as “treatment of conditions that will never 
cause symptoms, is futile or is excessive in complexity, duration, or cost when compared to accepted 
standards of care” (6). Overtreatment may seem innocuous in some cases (e.g., a patient has an extra 
blood test). In other cases (e.g., patients receiving chemotherapy or surgery that will not work for 
them), the harms are more apparent. Beyond the issue of cost, overtreatment exposes patients to the 
risks of adverse events from medications or procedures that they do not need.
In 2012, the American Board of Internal Medicine (ABIM), along with nine other specialty socie-
ties, released its Choosing Wisely campaign, focused on reducing overuse of specific medical tests 
or procedures in different health-care specialties. It includes an explicit goal of avoiding care that 
TABLe 1 | The society for gynecologic oncology choosing wisely (8).
•	 Do not screen low-risk women with CA-125 or ultrasound for ovarian 
cancer
 o CA-125 and ultrasound in low-risk, asymptomatic women have not led 
to diagnosis of ovarian cancer in earlier stages of disease or reduced 
ovarian cancer mortality. False-positive results of either test can lead to 
unnecessary procedures, which have risks of complication
•	 Do not perform colposcopy in patients treated for cervical cancer 
with Pap tests of low-grade squamous intraepithelial lesion (LGSiL) 
or less
 o Colposcopy for low-grade abnormalities in this group does not detect 
recurrence unless there is a visible lesion and is not cost-effective
•	 Do not perform Pap tests for surveillance of women with a history of 
endometrial cancer
 o Pap testing of the top of the vagina in women treated for endometrial 
cancer does not improve detection of local recurrence. False-positive 
Pap smears in this group can lead to unnecessary procedures, such as 
colposcopy and biopsy
•	 Avoid routine imaging for cancer surveillance in women with 
gynecologic cancer, specifically ovarian, endometrial, cervical, 
vulvar, and vaginal cancer
 o Imaging in the absence of symptoms or rising tumor markers has shown 
low yield in detecting recurrence or impacting overall survival
•	 Do not delay basic level palliative care for women with advanced 
or relapsed gynecologic cancer, and when appropriate, refer to 
specialty level palliative medicine
 o There is now an evidence-based consensus among physicians who care 
for cancer patients that palliative care improves symptom burden and 
quality of life. Palliative care empowers patients and physicians to work 
together to set appropriate goals for care and outcomes. Palliative care 
can and should be delivered in parallel with cancer directed therapies in 
appropriate patients
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is “unnecessary or whose harm may outweigh the benefits” (7). 
The recommendations provided by the Society for Gynecologic 
Oncology (SGO) are listed in Table 1 (8). These SGO recommen-
dations focus primarily on screening. Reducing overscreening 
and overtesting represents an important first step in controlling 
overuse. But these measures address low-hanging fruit – the most 
obvious or least remunerative examples of overused procedures.
As cancer treatment becomes increasingly expensive with the 
rapid development of precision medicine, eliminating overuse is 
crucial to a sustainable system of care. Easily identifiable targets 
of overuse in gynecologic cancers beyond those identified in the 
Choosing Wisely campaign exist. The purpose of this review is to 
explore strategies to reduce overtreatment in gynecologic cancers. 
This review will focus on the following specific examples selected 
by the authors as high priority areas where overtreatment can be 
curtailed: (1) the practice of lymphadenectomy and (2) postop-
erative radiation in early-stage endometrial cancer; (3) screening 
for recurrence in asymptomatic ovarian cancer patients; and (4) 
continuous chemotherapy for the treatment of ovarian cancer. 
Recommendations for reducing overtreatment are provided by 
the authors as opinions.
enDOMeTRiAL CAnCeR
Endometrial cancer is expected to be diagnosed in 60,050 
women in the United States in 2016, making it the most common 
gynecologic malignancy (9). Fortunately, most patients (80%) are 
diagnosed with local disease and will survive their cancer diagno-
sis. In fact, the majority of 5-year deaths in this population are due 
to the medical comorbidities frequently linked with endometrial 
cancer, including older age, obesity, and diabetes (10). Initial 
treatment includes a hysterectomy with salpingo-oophorectomy 
with surgical staging. Patients who develop metastatic recurrent 
disease have a poor prognosis and treatment options are limited 
(11). Because of the difficulty predicting who is at risk for recur-
rence, adjuvant treatment following hysterectomy is broadly 
prescribed to many with the goal of preventing recurrence in a 
few patients.
Although as a whole, clinical stage I endometrial cancer 
patients have a low risk for lymphatic metastasis, GOG 33 
showed that some risk factors (grade, depth of myometrial 
invasion, and vascular space invasion) do correlate strongly with 
lymphatic metastasis (12). The primary role of surgical staging 
for endometrial cancer is to identify the small subset of patients 
with lymphatic metastasis to the pelvic lymph nodes as these are 
patients known to benefit from adjuvant therapy. Unfortunately, 
none of this information is reliably available pre- or even intra-
operatively. The accuracy of preoperative tumor grade is poor, as 
20–25% of cases that are grade 1 on biopsy will be upgraded after 
hysterectomy. Accuracy of depth of invasion at frozen section is 
similarly disappointing, especially when performed outside of 
high volume centers with experienced pathologists. A prospec-
tive, blinded study of the accuracy of frozen section revealed that 
tumor grade at frozen section correlated with final pathology in 
only 58% of cases, while depth of invasion correlated in 67% of 
patients. Overall, 28% of patients were upstaged from the intra-
operative assessment to final pathology (13).
Surgical staging had been the norm for decades, its practice 
reinforced by retrospective studies showing a survival benefit 
in patients with high-risk features who underwent a systematic 
pelvic and para-aortic lymphadenectomy (14, 15). This surgical 
dogma has been questioned after two prospective randomized 
trials, evaluating that the value of lymph node dissection at the 
time of hysterectomy (ASTEC, CONSORT) failed to demonstrate 
a survival advantage with lymphadenectomy while confirming 
significant morbidity with the procedure (16, 17). The morbidity 
associated with lymph node dissection includes direct surgical 
morbidity (increased intraoperative time, greater blood loss, 
and risk of surgical complications) as well as the long-term 
consequences of lymphedema. Despite criticisms of these stud-
ies, including (1) a low-risk patient population with a low prob-
ability of nodal metastases and (2) the inconsistent application of 
information obtained from the nodal dissection to guide adjuvant 
therapy, these studies reflect many of the real world issues faced 
by clinicians caring for endometrial cancer patients.
Prospective studies examining the value of postoperative 
adjuvant treatment in patients with apparent early-stage disease 
but no lymphatic assessment have failed to demonstrate a survival 
benefit (11, 18–20). In the 1970s, a randomized prospective trial 
of postoperative whole pelvic radiation versus brachytherapy 
alone concluded that although radiation decreased recurrence 
rates, it had no effect on overall survival. More than 20 years of 
follow-up to this study revealed decreased long-term survival 
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and increased secondary malignancies following postoperative 
whole pelvic radiation (21). The finding that the reduction of 
locoregional recurrence after pelvic radiation was not associated 
with a survival advantage has been confirmed subsequently by 
PORTEC-1, GOG-99, and ASTEC (11, 17, 19). The PORTEC-2 
trial showed that vaginal brachytherapy provides equivalent 
locoregional control when compared to whole pelvic radiation 
with fewer adverse effects and improved quality of life (18). Low-
risk patients (Stage 1A and B, Grades 1 and 2) randomized to 
vaginal brachytherapy or observation have been shown to have 
similar recurrence risks (22). Despite flaws in many of these trials 
(e.g., underpowered for a survival outcome), adjuvant radiation is 
not recommended for women with low-risk disease (23).
Early-stage endometrial cancer patients who are observed 
after surgery, although overall more likely to recur, are more likely 
to have isolated vaginal recurrences than women treated with 
adjuvant radiation (19–21, 24). Salvage rates for isolated pelvic 
recurrences with modern radiation techniques have been shown 
to be high (24, 25).
Trends in the use of lymphadenectomy in women who 
underwent surgery for endometrioid adenocarcinoma of the 
endometrium in the United States were recently analyzed using 
the surveillance, epidemiology, and end results (SEER) cancer 
registry between 1998 and 2012. Investigators found that a 
decreased frequency of lymphadenectomy from 2007 to 2012 
was not associated with a change in the proportion of women 
found to have lymphatic metastasis. Interestingly, a small increase 
in survival accompanied the decrease in lymphadenectomy (26).
The identification of endometrial Cancer 
Patients who Can Safely Avoid 
Lymphadenectomy
Accurate identification of the small number of patients with 
lymphatic metastasis remains crucial as lymphadenectomy for 
these patients can have prognostic and possibly therapeutic value. 
When high-risk features are identified after hysterectomy only, 
clinicians must decide between returning to the operating room 
for a staging lymphadenectomy or basing treatment decisions on 
uterine factors, an approach that has a significant risk of result-
ing in overtreatment with postoperative adjuvant radiation as 
the majority of patients at “high risk” for lymphatic metastasis 
actually do not have metastatic disease (27).
Using a composite index of traditional risk factors for recur-
rence, investigators from the Mayo Clinic have identified a sub-
group of patients at very low risk for lymph node metastasis. In a 
series of 328 patients treated at the Mayo Clinic with grade 1 or 2 
endometrioid tumors, <2 cm in diameter and <50% myometrial 
invasion identified at time of intraoperative frozen section, the 
rate of nodal metastasis was 5% and 5-year survival was 97% 
(28). These criteria were further examined prospectively through 
a multi-institutional evaluation that noted a negative predictive 
value of 98.2% (29, 30). Broader utilization of these criteria could 
potentially eliminate unnecessary lymphadenectomies in women 
with endometrial cancer.
Sentinel lymph node biopsies (SLN) have been proposed as a 
surgical alternative to complete lymphadenectomy in patients with 
apparent early-stage endometrial cancer. The goal of SLN map-
ping is to accurately identify lymph node metastases while saving 
patients from the morbidity of complete lymphadenectomy. The 
utility of this technique as a strategy to reduce overtreatment has 
been firmly established in other disease sites (breast cancer and 
melanoma); however, the value and positive predictive value of 
SLN mapping in endometrial cancer has not been explored outside 
of single institution studies. Whether SLN biopsy can prevent the 
perioperative morbidity and long-term sequelae of lymphedema 
in this population without increasing recurrence rates and disease-
related mortality is an important clinical question.
The identification of endometrial Cancer 
Patients who Can Safely Avoid Adjuvant 
Radiation
The strongest argument for lymphadenectomy in early endo-
metrial cancer is that women with a lymph node sampling may 
be able to safely avoid adjuvant radiation. Information obtained 
from lymph node dissection influences the prescription of 
postoperative adjuvant radiation. A report of 181 women, with 
a diagnosis of grade 1 endometrial cancer, who underwent 
staging lymphadenectomy found that 19% of the neoplasms 
were upgraded, 18% were upstaged, while adjuvant therapy was 
affected by the results of lymphadenectomy in 26% of women 
(31). Women without surgical staging received radiation at 
higher rates than those with information available regarding 
their lymph node status. The application of newer surgical 
algorithms (using Mayo criteria to select patients who need 
lymphadenectomy) and validation of the practice of SLN could 
potentially reduce overprescribing of adjuvant radiation without 
resorting to lymphadenectomies for all.
Recent advances in molecular technology may provide addi-
tional insight into the identification of patients with a good prog-
nosis who may not require treatment beyond a hysterectomy. The 
Cancer Genome Atlas (TCGA) performed an integrated molecu-
lar analysis of 373 endometrial tumors and was able to define four 
groups based on genomic characterization of mutation profiles, 
and to furthermore demonstrate that these groups correlate with 
prognosis. One of these groups (POLE-mutant) carried an excep-
tionally good prognosis (32). Between 4 and 12% of endometrial 
cancers are POLE-mutated and this genetic abnormality does 
not necessarily map onto traditional histopathological categories 
(32–35). Updated molecular classifications of disease to predict 
biologic behavior are needed. An assay able to identify patients 
at low risk for recurrence would transform treatment for this 
disease.
OvARiAn CAnCeR
Ovarian cancer is the most lethal of the gynecologic cancers. In 
the United States in 2016, there will be an estimated 22,280 cases 
and 14,240 deaths related to this disease (9). Among women 
with stage III or IV ovarian cancer, 5-year survival is only 
10–25% despite aggressive treatment with surgery and adjuvant 
chemotherapy. Despite high response rates to initial therapy, 
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FiGURe 1 | Lead time bias that develops from early screening for cancer recurrence.
4
Temkin et al. Overtreatment and Gynecologic Cancer
Frontiers in Oncology | www.frontiersin.org May 2016 | Volume 6 | Article 118
poor prognosis associated with a diagnosis of epithelial ovarian 
cancer is due both to the advanced stage of disease at the time 
of diagnosis and the eventual development of chemotherapy-
resistant disease. However, this disease is heterogeneous and 
there is considerable variability in survival even among patients 
diagnosed at an advanced stage (36). A reliable molecular signa-
ture identifying patients with a better or worse prognosis has not 
yet been identified.
Because of the high relapse rates, the follow-up of women 
treated for ovarian cancer represents a challenge for the gyneco-
logic oncologist. Cancer surveillance following initial treatment 
and complete response is essentially screening for early relapse. 
In order for a screening test to be effective, effective treatment 
for the disease (in this case early relapse) must be available and 
the treatment of early relapse would have to be more effective 
than the treatment of late relapse. In the setting of platinum 
resistant disease, few therapeutic options prolong survival. In 
the setting of platinum-sensitive ovarian cancer, retreatment 
with platinum-based combination chemotherapy results in high 
complete response rates. As the platinum-free interval extends, 
the response rates to retreatment become even higher.
One of the harms of this screening for recurrent ovarian 
cancer is the development of a lead time bias (Figure 1). Early 
diagnosis of recurrent disease exposes the patient to additional 
chemotherapy without this improving overall survival and may 
limit treatment further into the disease course. Many women with 
ovarian cancer receive multiple imaging tests per year and lifelong 
chemotherapy once recurrent disease is diagnosed. Both imag-
ing and continuous chemotherapy are of little value in changing 
survival from this disease but are commonly prescribed (37, 38).
The Utility of Following CA-125 Levels in 
improving Survival from Ovarian Cancer
Cancer antigen 125 (CA-125) is a glycoprotein that is the current 
standard of care biomarker for ovarian cancer surveillance. More 
than 80% of women with advanced-stage ovarian cancer have an 
elevated level of CA-125 at the time of initial diagnosis. Periodic 
follow-up measurements of CA-125 levels after treatment for 
ovarian cancer allow the detection of recurrences months before 
symptoms or signs appear, since the CA-125 level generally 
increases 2–6  months before a recurrence is radiologically or 
clinically detectable (39). However, treatment for recurrence 
in asymptomatic women with an increased CA-125 level and a 
history of ovarian cancer has not been shown to alter survival. 
In a landmark study conducted by the European Organisation 
for Research and Treatment of Cancer (MRC OV05/EORTCC 
55955), 529 women who experienced a complete clinical remis-
sion after undergoing initial treatment for ovarian cancer were 
randomized to undergo treatment for recurrence either (1) 
immediately after detection of a rise in the level of CA-125 or (2) 
after the onset of symptoms, regardless of the CA-125 level. No 
evidence of a survival benefit was found with early treatment for 
recurrence (27.1 versus 25.7 months) on the basis of an elevated 
CA-125 concentration. Women who were in the early group 
had earlier deterioration in quality of life versus women in the 
delayed treatment group (40). Criticisms of this study included 
enrollment of poor prognosis women, changes in second-line 
chemotherapy options for ovarian cancer, and low rates of sec-
ondary cytoreduction (41). A retrospective study of 121 patients 
undergoing secondary cytoreduction did suggest an advantage 
for patients whose recurrence was discovered through screening 
(42). This single institution study may have been biased by its 
retrospective nature and the tertiary care setting. Overall, there is 
no clear evidence that surveillance impacts survival compared to 
waiting for the presentation of symptoms (41, 43).
The Utility of Routine imaging in improving 
Survival from Ovarian Cancer
Expert recommendations include obtaining imaging in 
patients with a history of ovarian cancer only in women with 
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an increasing tumor marker or with symptoms worrisome for 
recurrence (41, 44). Computerized tomographic scans (CT) 
are currently the imaging modality of choice for the evalua-
tion of suspected ovarian cancer recurrences. Given the lack 
of evidence that surveillance using the level of CA-125 present 
in blood samples prolongs survival, it is implausible that the 
early detection of recurrence through routine CT scanning 
could result in any significant increase in survival (40). These 
clinical limitations of CT make magnetic resonance imaging 
(MRI) and positron emission tomography (PET) imaging with 
their added expense and potentially increased false-positive 
rates challenging to justify in the asymptomatic ovarian cancer 
patient.
Chemotherapy and the Treatment of 
Asymptomatic Disease
The majority of ovarian cancer patients will relapse within 
5 years and, therefore, require salvage chemotherapy. Although 
improvements in chemotherapy have increased overall survival, 
recurrent ovarian cancer remains a lethal disease. Because salvage 
treatments are not curative, the goals of treatment in this setting 
are to extend survival through disease control and palliation of 
cancer symptoms. An emphasis on an individual patient’s quality 
of life is crucial.
A 2006 study evaluated ovarian cancer survival with the SEER 
database for patients treated with chemotherapy by a medical 
oncologist or gynecologic oncologist. Although both groups of 
physicians are trained to provide medical treatment to ovarian 
cancer patients, substantial differences in the patterns of care 
emerged based on the patient’s provider. During the first 5 years 
of care for ovarian cancer, patients treated by medical oncologists 
received more weeks of chemotherapy than patients treated by 
gynecologic oncologists (patient mean, 16.5 versus 12.1 weeks, 
respectively, P < 0.0023). This increase in chemotherapy admin-
istration translated to increased adverse events. Gynecologic 
oncology patients had fewer weeks that included chemotherapy-
associated adverse events than medical oncology patients (patient 
mean, 8.9 versus 16.2 weeks, respectively, P < 0.0001). No sur-
vival advantage was achieved for patients receiving chemotherapy 
administered by a medical oncologist (37).
COnCLUSiOn
As we strive toward defining quality measures in health care in 
the United States, defining best practices for women with gyneco-
logic cancer should be a priority. Further research in endometrial 
cancer should be focused on defining which women with this dis-
ease can safely avoid lymphadenectomy and post-hysterectomy 
radiation and providing evidence that postoperative surveillance 
is safe such that practitioners feel comfortable making this 
recommendation. Best practices for post-treatment surveillance 
in ovarian cancer patients should be individualized, taking into 
account the clinical benefit of second-line therapy, costs, morbid-
ity and mortality of the surveillance methods, available treatment 
options, and patient preference.
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